Our lead compound, GLIX1, is in clinical development for glioblastoma through Tetragon, a joint venture of Hemispherian and BioLineRx (Nasdaq:BLRX). At the preclinical stage, is GLIX8, which is indicated in a much broader range of cancers. Further compounds are in the early stages of discovery.
